Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,351 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06636162RecruitingEarly Phase 1
Testing DSP-0390 before surgery for gliomas
This trial tests a drug called DSP-0390 in people with gliomas (a type of brain tumor). You take the drug for a short time before your scheduled surgery to see how it affects the tumor. It might help doctors find new ways to treat these tumors.
St Louis, MissouriAges 18 years+ - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06649253Recruiting
CD9 Gene and Relapse in Childhood B-ALL Study
This study looks at how a gene called CD9 might affect relapse in children with B-ALL. It involves extra blood or bone marrow tests to understand why some children relapse.
AngersAges birth–17 years - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+ - NCT06651606Recruiting
Preventing relapse of problem behavior in kids with disabilities
This trial tests a new approach to help children and young adults with intellectual and developmental disabilities reduce problem behaviors and avoid relapses. It uses ideas from behavioral economics to find what works best for each person.
Auburn, AlabamaAges 6–21 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT06674265RecruitingPhase 1
Natural killer cells for advanced neuroblastoma
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
TehranAges 2–16 - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06686524RecruitingPhase 1
CD19-targeted UCAR-T for refractory juvenile dermatomyositis
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Hangzhou, ZhejiangAges 5 years+ - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT07136545RecruitingPhase 1/Phase 2
HCB101 plus pembrolizumab for advanced head and neck cancer
This trial tests a new drug, HCB101, combined with the immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread and is no longer responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Taoyuan, Guishan DistrictAges 18 years+ - NCT06641271Enrolling by invitation
Vagus nerve stimulation with hand exercises for MS
This study tests if vagus nerve stimulation (a mild electrical pulse on the ear) combined with hand exercises can help repair the protective coating of your nerves and improve hand function in multiple sclerosis.
Aurora, ColoradoAges 18–70 - NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT06721962RecruitingPhase 1/Phase 2
Testing an experimental treatment for moderate to severe Crohn's disease
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Scottsdale, ArizonaAges 18–65 - NCT06732219Recruiting
Pilot trial to prevent relapse of severe problem behavior
This trial tests a new way to help children and teens with intellectual or developmental disabilities (IDD) avoid relapsing into severe problem behaviors like aggression or self-injury. It focuses on behaviors that are triggered by wanting attention or access to favorite items.
Auburn, AlabamaAges 6–17 - NCT06733922RecruitingPhase 4
Tracking MS changes with ofatumumab in active relapsing MS
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Calgary, AlbertaAges 18–99 - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT06735248RecruitingPhase 2
Study testing mRNA vaccine for multiple sclerosis relapse prevention
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
Boston, MassachusettsAges 18–55 - NCT06747156RecruitingEarly Phase 1
mRNA medicine for refractory autoimmune diseases
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06771544RecruitingPhase 2
Cyclophosphamide and pembrolizumab for advanced melanoma
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Orange, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,351 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.